A PHASE II DOUBLE BLIND, RANDOMISED CONTROLLED TRIAL OF VEGF INHIBITOR AXITINIB MONOTHERAPY WITH EARLY DYNAMIC CONRAST ENHANCED ULTRASOUND MONITORING IN CHEMOREFRACTORY THIRD LINE METASTATIC COLORECTAL CANCER

Trial Profile

A PHASE II DOUBLE BLIND, RANDOMISED CONTROLLED TRIAL OF VEGF INHIBITOR AXITINIB MONOTHERAPY WITH EARLY DYNAMIC CONRAST ENHANCED ULTRASOUND MONITORING IN CHEMOREFRACTORY THIRD LINE METASTATIC COLORECTAL CANCER

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2016

At a glance

  • Drugs Axitinib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms AXMUS-C
  • Most Recent Events

    • 28 Jan 2016 Accrual to date is 76% according to United Kingdom Clinical Research Network.
    • 03 Dec 2015 Accrual to date is 74% according to United Kingdom Clinical Research Network.
    • 25 Oct 2015 Accrual to date is 72% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top